Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.17 +0.12 (+0.44%)
Streaming Delayed Price Updated: 9:38 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
39 40 Next >
Pfizer Inc. (NYSE: PFE) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
From Pfizer Inc.
Via Business Wire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
Via Investor Brand Network
News headline image
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
News headline image
Don't Be Fooled by These 3 Value Traps
Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold. 
Via MarketBeat
News headline image
Smartsheet Can Bolster Workflow Ecosystems and Your Portfolio
Cloud-based collaborative work management software provider Smartsheet Inc. (NASDAQ: SMAR) is an under-the-radar name growing at 35%. 
Via MarketBeat
News headline image
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
News headline image
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later 
Via MarketBeat
News headline image
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
News headline image
MarketBeat Week in Review – 3/13 - 3/17
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week 
Via MarketBeat
Topics ETFs Economy
News headline image
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock 
Via MarketBeat
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Pfizer Invests $43 Billion to Battle Cancer
From Seagen Inc.
Via Business Wire
News headline image
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
From Pfizer Inc.
Via Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
News headline image
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Lucy Scientific Discovery, Inc. Scores Major Milestone, Transitions To Revenue Generating Company With First Commercial Sale Of Psilocybin ($LSDI)
Via AB Newswire
News headline image
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
News headline image
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
Via MarketBeat
Topics Bankruptcy
News headline image
Dr. Harte asks: “‘Public Health?’ THE serious hazard to health?”
Corte Madera, California, United States - 02-22-2023 (PR Distribution™) - 
Via PR Distribution
News headline image
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.